Background: Limited clinical data exist describing the use of direct-acting oral
anticoagulants (DOACs) in patients with body mass index (BMI)> 40 kg/m2 or body weight> …

Anticoagulation therapy is recommended for patients with non-valvular atrial fibrillation
(NVAF) and an increased risk of stroke. Although apixaban showed superiority over warfarin …

Background Direct oral anticoagulants such as dabigatran are the preferred anticoagulant in
treating atrial fibrillation (AF) patients due to their effectiveness and safety. Whether this …

In the last 40 years, concern about the obesity epidemic has increased. Data from the
current literature highlight a strong relationship between obesity and atrial fibrillation (AF) …

Background Guidance for dabigatran and rivaroxaban in overweight patients diagnosed
with non-valvular atrial fibrillation (NVAF) is still lacking. Aim Compare the effectiveness and …

Background Patients with obesity were underrepresented in studies evaluating the safety
and effectiveness of direct oral anticoagulants (DOAC) in patients with non-valvular atrial …

Aim: Evaluate healthcare resource utilization (HRU) and costs associated with rivaroxaban
and warfarin among nonvalvular atrial fibrillation (NVAF) patients with obesity and …

BACKGROUND: The efficacy and safety of non–vitamin-K antagonist oral anticoagulants
(NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain …

Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …

Background Obesity and atrial fibrillation (AF) frequently coexist and independently increase
mortality. We sought to assess the association between obesity and adverse events in …